PL3239153T3 - Pochodne 9-(1H-imidazol-5-ilo)-1,11-dihydroizochromeno[4',3':6,7]nafto[1,2-d]imidazolu i ich zastosowanie jako inhibitorów NS5A HCV - Google Patents

Pochodne 9-(1H-imidazol-5-ilo)-1,11-dihydroizochromeno[4',3':6,7]nafto[1,2-d]imidazolu i ich zastosowanie jako inhibitorów NS5A HCV

Info

Publication number
PL3239153T3
PL3239153T3 PL17160683T PL17160683T PL3239153T3 PL 3239153 T3 PL3239153 T3 PL 3239153T3 PL 17160683 T PL17160683 T PL 17160683T PL 17160683 T PL17160683 T PL 17160683T PL 3239153 T3 PL3239153 T3 PL 3239153T3
Authority
PL
Poland
Prior art keywords
dihydroisochromeno
naphtho
imidazol
inhibitors
imidazole derivatives
Prior art date
Application number
PL17160683T
Other languages
English (en)
Polish (pl)
Inventor
Elizabeth M. Bacon
Jeromy J. Cottell
John O. Link
Teresa Alejandra Trejo Martin
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of PL3239153T3 publication Critical patent/PL3239153T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17160683T 2012-05-16 2013-05-15 Pochodne 9-(1H-imidazol-5-ilo)-1,11-dihydroizochromeno[4',3':6,7]nafto[1,2-d]imidazolu i ich zastosowanie jako inhibitorów NS5A HCV PL3239153T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261647966P 2012-05-16 2012-05-16
US13/831,116 US20130309196A1 (en) 2012-05-16 2013-03-14 Antiviral compounds
EP17160683.3A EP3239153B1 (en) 2012-05-16 2013-05-15 9-(1h-imidazol-5-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazole derivatives and their use as inhibitors of hcv ns5a
EP13726936.1A EP2850085B1 (en) 2012-05-16 2013-05-15 Antiviral compounds inhibitors of hcv ns5a
PCT/US2013/041201 WO2013173488A1 (en) 2012-05-16 2013-05-15 Antiviral compounds inhibitors of hcv ns5b

Publications (1)

Publication Number Publication Date
PL3239153T3 true PL3239153T3 (pl) 2019-09-30

Family

ID=49581469

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13726936T PL2850085T3 (pl) 2012-05-16 2013-05-15 Antywirusowe związki inhibitorowe hcv ns5a
PL17160683T PL3239153T3 (pl) 2012-05-16 2013-05-15 Pochodne 9-(1H-imidazol-5-ilo)-1,11-dihydroizochromeno[4',3':6,7]nafto[1,2-d]imidazolu i ich zastosowanie jako inhibitorów NS5A HCV

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13726936T PL2850085T3 (pl) 2012-05-16 2013-05-15 Antywirusowe związki inhibitorowe hcv ns5a

Country Status (19)

Country Link
US (5) US20130309196A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP3239153B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP6209209B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR20200017557A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN109970749A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2013262874B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014028221B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2873485C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (2) EA034749B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2628350T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1245262B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL235645A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014MN02459A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX362060B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL2850085T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT3239153T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG10201703451RA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI3239153T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013173488A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
KR20180026563A (ko) 2010-11-17 2018-03-12 길리애드 파마셋 엘엘씨 항바이러스 화합물
BR112013012091A2 (pt) 2011-11-16 2019-09-10 Gilead Sciences Inc compostos antivirais, seu uso e composição farmacêutica
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
WO2015030854A1 (en) * 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
CN106715446B (zh) * 2014-07-02 2019-11-08 路易斯安那泽维尔大学 使含至少一个酚基(或芳羟基)的药物分子提高生物利用度和降低剂量要求的硼基前药策略
HUE056470T2 (hu) 2014-12-26 2022-02-28 Univ Emory Vírusellenes N4-Hidroxicitidin származékok
CA3017020C (en) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3452038B1 (en) * 2016-05-05 2022-07-06 Laurus Labs Limited Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors
EP3463469B1 (en) 2016-05-27 2023-12-13 Gilead Sciences, Inc. Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans
CN108368123B (zh) * 2016-07-08 2021-02-19 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
CN106220639A (zh) * 2016-07-22 2016-12-14 上海众强药业有限公司 一种维帕他韦中间体新晶型
CN107573355B (zh) * 2016-11-30 2020-03-17 上海博志研新药物技术有限公司 维帕他韦、其中间体及制备方法
MX2020002191A (es) 2017-08-28 2020-10-05 Enanta Pharm Inc Agentes antivirales contra la hepatitis b.
CN107501280A (zh) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 一种维帕他韦的合成方法
PH12022550371A1 (en) 2017-12-07 2023-05-03 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR102819704B1 (ko) 2018-11-21 2025-06-11 이난타 파마슈티칼스, 인코포레이티드 항바이러스제로서의 작용화된 헤테로사이클
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
US20230257348A1 (en) * 2020-08-18 2023-08-17 Merck Sharp & Dohme Llc Cyclopentapyrrole orexin receptor agonists
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN117460734A (zh) * 2021-05-21 2024-01-26 吉利德科学公司 作为寨卡病毒抑制剂的五环衍生物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2003007945A1 (en) * 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CA2522574C (en) * 2003-05-09 2015-07-07 Boehringer Ingelheim International Gmbh Hepatitis c virus ns5b polymerase inhibitor binding pocket
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
EA200700336A1 (ru) 2004-07-16 2009-12-30 Джилид Сайэнс, Инк. Противовирусные соединения
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ587323A (en) 2008-02-12 2012-02-24 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5312486B2 (ja) 2008-02-13 2013-10-09 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
MX2011005896A (es) 2008-12-03 2011-09-29 Presidio Pharmaceuticals Inc Inhibidores de hcv ns5a.
CA2753313A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR20130130875A (ko) 2009-02-27 2013-12-02 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 ｃ형 간염 억제제
CA2760205A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
CN104230900B (zh) * 2009-05-13 2018-10-19 吉利德制药有限责任公司 抗病毒化合物
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011028596A1 (en) 2009-09-04 2011-03-10 Glaxosmithkline Llc Chemical compounds
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010341537A1 (en) 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
ES2558554T3 (es) 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US20130296311A1 (en) * 2010-05-28 2013-11-07 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2616461A4 (en) 2010-08-26 2014-03-26 Rfs Pharma Llc POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
US8999967B2 (en) * 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
KR20180026563A (ko) * 2010-11-17 2018-03-12 길리애드 파마셋 엘엘씨 항바이러스 화합물
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
BR112013012091A2 (pt) * 2011-11-16 2019-09-10 Gilead Sciences Inc compostos antivirais, seu uso e composição farmacêutica
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
JP6209209B2 (ja) 2017-10-04
PT2850085T (pt) 2017-06-26
CA2873485A1 (en) 2013-11-21
US20170342085A1 (en) 2017-11-30
AU2013262874B2 (en) 2017-11-02
ES2738012T3 (es) 2020-01-17
PT3239153T (pt) 2019-07-30
HK1205126A1 (en) 2015-12-11
EP2850085A1 (en) 2015-03-25
EP3239153B1 (en) 2019-05-08
MX2014013660A (es) 2015-04-17
JP2017160276A (ja) 2017-09-14
CN109970749A (zh) 2019-07-05
AU2017248566A1 (en) 2017-11-09
KR20200017557A (ko) 2020-02-18
CN104487442A (zh) 2015-04-01
US20140316144A1 (en) 2014-10-23
BR112014028221A2 (pt) 2020-10-27
SI2850085T1 (sl) 2017-08-31
AU2013262874A2 (en) 2015-01-22
EA034749B1 (ru) 2020-03-17
WO2013173488A1 (en) 2013-11-21
CN104487442B (zh) 2016-10-26
CN106432254A (zh) 2017-02-22
JP2015517527A (ja) 2015-06-22
EP3239153A1 (en) 2017-11-01
IL235645A0 (en) 2015-02-01
US20160115175A1 (en) 2016-04-28
CN106432254B (zh) 2018-12-28
US10800789B2 (en) 2020-10-13
AU2019204423A1 (en) 2019-07-11
JP6408656B2 (ja) 2018-10-17
EA028026B1 (ru) 2017-09-29
EA201790963A1 (ru) 2018-02-28
CA2873485C (en) 2020-05-05
HK1245262B (en) 2020-01-10
MX362060B (es) 2019-01-07
SG10201703451RA (en) 2017-06-29
SI3239153T1 (sl) 2019-08-30
US20190337960A1 (en) 2019-11-07
EP2850085B1 (en) 2017-03-15
AU2013262874A1 (en) 2014-12-11
BR112014028221B1 (pt) 2022-05-03
EA201492002A1 (ru) 2015-11-30
KR102078233B1 (ko) 2020-02-17
PL2850085T3 (pl) 2017-10-31
SG11201407533SA (en) 2014-12-30
US9682989B2 (en) 2017-06-20
KR20150008908A (ko) 2015-01-23
ES2628350T3 (es) 2017-08-02
US20130309196A1 (en) 2013-11-21
IN2014MN02459A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-10

Similar Documents

Publication Publication Date Title
PL3239153T3 (pl) Pochodne 9-(1H-imidazol-5-ilo)-1,11-dihydroizochromeno[4',3':6,7]nafto[1,2-d]imidazolu i ich zastosowanie jako inhibitorów NS5A HCV
ZA201409215B (en) Macrocyclic inhibitors of flaviviridae viruses
IL236006A0 (en) Macrocyclic inhibitors of flavoviride viruses
SI2861604T1 (sl) Makrociklični inhibitorji flavivirusov
IL235275B (en) 2,2-difluoropropionamide derivatives of methyl bardoxolone, their polymorphic forms and methods of using them
SI2649076T1 (sl) Makroklinični inhibitorji flavivirusov
ZA201305612B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
IL224178A (en) Heterogeneous history of cervix as hcv inhibitors
SG11201400484RA (en) Novel heterocyclic derivatives and their uses
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
AP2013007147A0 (en) Use of substituted 2,3-dihydroimidazo[1,2-C]quinyzolines
ZA201405265B (en) Derivatives of aza adamantane and uses thereof
PL2709584T3 (pl) Zastosowanie sensoryczne pochodnych 6-cyklopentylidenoheksanu
EP2638402A4 (en) PROOF OF ADENYLATE CYCLASES
AU2012904267A0 (en) Squid, calamari of cuttlefish jig